Sign in
XRTX Stock Price, Chart, Stats & News
XORTX Therapeutics Inc.
Save
XORTX Therapeutics Inc. (XRTX) does not currently pay a dividend.
470,646
Market cap
–
Current P/E
0.96x
Forward P/E
XRTX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -78.35% |
ROE | -111.11% |
D/E | 0.02x |
Interest coverage ratio | – |
XRTX valuation
P/E | – |
P/S | – |
P/B | 0.17x |
P/CF | -0.16x |
P/FCF | -0.17x |
P/OCF | -0.16x |
PEG | 0.00x |
EV multiple | -0.50x |
About
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications.
Similar securities
Based on sector and market capitalization
Report issue